Calgary, Canada
Qualisure Diagnostics Inc. is at the forefront of precision oncology with its innovative approach to molecular diagnostics. Founded in 2017 and headquartered in Canada, this biotechnology startup is revolutionizing cancer treatment personalization through its proprietary Molecular deCodeR™ platform.
The company's slogan, "Deploying AI-enabled molecular diagnostics globally through decentralized testing and centralized interpretation," encapsulates its mission. By leveraging the synergy of molecular biology, artificial intelligence, and cloud-based solutions, Qualisure enhances diagnostic accuracy and accessibility worldwide without necessitating new infrastructure at each location.
Qualisure's flagship product, Thyroid GuidePx®, offers actionable insights for papillary thyroid cancer, streamlining treatment by identifying recurrence risks. The company collaborates with academic, clinical, and global partners, broadening its reach and impact. Having secured its latest investment as a Convertible Note in November 2022, Qualisure is well-positioned for further growth in the rapidly evolving life sciences sector.
